The HIV virologic outcomes of different interventions among treatment-experienced patients with 2 consecutive detectable low-level viremia

Journal of the International Association of Physicians in AIDS Care

Volumn 10, Issue 1, 2011, Pages 54-56

  Pham, Tri ^a   Alrabaa, Sally ^a   Somboonwit, Charurut ^a   Hung, Le ^b   Montero, Jose ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

blips; resistance; treatment experienced; viremia; virologic failure

Indexed keywords

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; GENOTYPE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; RETROSPECTIVE STUDY; VIRUS LOAD;

GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; RETROSPECTIVE STUDIES; VIRAL LOAD; VIREMIA;

EID: 79952307803     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109710385122     Document Type: Article

References (12)

1. Ddhs Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. December 2009. Available at http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed July 1, 2010.
2. Lanoy E., May M., Mocroft A., et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 2009 ; 23 (16). 2199-2208.
3. Hull M. Persistent low-level viremia is associated with increased risk of virologic failure and mortality. Conference of Retroviruses and Opportunistic Infections. San Francisco. February16-19, 2010.
4. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis. 2004 ; 39 (7). 1030-1037. (Pubitemid 39313462)
5. Nettles RE, Kieffer TL, Kwon P., et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005 ; 293 (7). 817-829. (Pubitemid 40250365)
6. Hermankova M., Ray SC, Ruff C., et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 2001 ; 286 (2). 196-207. (Pubitemid 32640851)
7. Havlir DV, Bassett R., Levitan D., et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA, 2001 ; 286: 171-179. (Pubitemid 32640848)
8. Sungkanuparph S., Groger RK, Overton ET, Fraser VJ, Powderly WG Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med. 2006 ; 7 (7). 437-441. (Pubitemid 44269810)
9. Deeks SG, Grant RM, Wrin T., et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003 ; 17 (3). 361-370. (Pubitemid 36223261)
10. Sirvent JL, Socas MM, Calzadilla CH, Lirola AM, Valls MR Utility of interrupting antiretroviral treatment before HIV drug resistance testing in patients with persistently detectable low-level viremia. J Acquir Immune Defic Syndr. 2005 ; 40 (1). 111-113. (Pubitemid 41233216)
11. McMahon D. Short-course raltegravir intensification does not reduce persistent low-level viremia in patientswith HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010 ; 50 (6). 912-919.
12. Evering T. The antiviral and immunological effects of intensification of suppressive ART with Maraviroc, a CCR5 antagonist. Conference of Retroviruses and Opportunistic Infections. San Francisco. February16-19, 2010.